This site is intended for healthcare professionals
News

FDA accepts refiling of intravenous (IV) meloxicam for the management of moderate to severe pain.- Baudax Bio

Read time: 1 mins
Published:27th Jan 2020
Baudax Bio, Inc. a specialty pharmaceutical company focused on therapeutics for acute care settings, announced that the FDA has set a PDUFA goal date of 2 February 2020 for its decision on the New Drug Application (NDA) for intravenous (IV) meloxicam for the management of moderate to severe pain. The assignment of this PDUFA goal date follows the FDA’s acceptance of Baudax’s latest complete response package relating to its 2019 complete response letter (CRL) and appeal filing, seeking approval for IV meloxicam..
Condition: Pain:Post Surgical
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.